Hypotension Archives - MPR

Hypotension

Antiarrhythmic Agent Linked to Patient’s Blue-Gray Skin Discoloration

A recent report published in the New England Journal of Medicine describes the case of a patient with persistent skin discoloration associated with the use of the antiarrhythmic agent amiodarone. The 81-year-old man presented to the emergency department after a fall, which was eventually attributed to orthostatic hypotension. His medical history included atrial fibrillation and…

MPR Weekly Dose Podcast: Episode 15

Back from our Thanksgiving break, this week we talk about the new approval for sickle cell disease; the re-introduction of a product that was taken off the market in the 60’s; The first ready-to-use phenylephrine injection; A new ultrasound enhancing agent; And an approval for arthritis.

Biorphen, a Ready-to-Use Phenylephrine Formulation, Now Available

Eton Pharmaceuticals announced the availability of Biorphen (phenylephrine HCl) injection as the first ready-to-use injectable formulation of phenylephrine. Biorphen, an α-1 adrenergic receptor agonist, is indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. It is supplied as a 0.1mg/mL solution in 5mL single-dose ampules; this corresponds…

FDA: Cybersecurity Vulnerabilities Identified With Certain Medical Devices, Hospital Networks

The Food and Drug Administration (FDA) has issued an alert regarding a set of cybersecurity vulnerabilities that may potentially introduce risks for certain medical devices and hospital networks.  Security researchers have determined 11 vulnerabilities, referred to as “URGENT/11”, that may potentially allow an unauthorized user to take control of a facilities’ medical network leading to…